Topics:
Hematologic Malignancies • Pediatric Oncology • Medical Oncology • Bone Marrow Transplant • Hematology
How do you manage steroid-refractory acute GVHD following allogeneic transplant?
What criteria do you use to define steroid-refractory disease?
Does your management different by organ system involved - GI vs skin vs other?
Answer from: Medical Oncologist at Academic Institution
The short answer is to enroll the patient in a well-designed clinical trial, if available. If not, I would start with ruxolitinib based on the REACH2 trial (Zeiser et al., PMID 32320566) which was multicenter, randomized, open-label, phase 3 trial comparing the efficacy and safety of oral ruxol...
Sign in or Register to read more